Alexandra Herzlich, MD
Cornea and External Diseases Specialist · New York, NYNPI 1932360997
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 80 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $716, 2.1 times the $343 reported in 2019.
Across 80 payments — averaging $31.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kala Pharmaceuticals, Inc.$488
- Biotissue Holdings Inc.$301
- Dompe US, Inc.$284
- Sun Pharmaceutical Industries Inc.$278
- Bausch & Lomb, A Division Of Bausch Health US, LLC$220
- Glaukos Corporation$168
- plus $767 from 13 others
What the payments were for
- Food & beverage$2,507100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kala Pharmaceuticals, Inc. | 12 | $488 |
| Biotissue Holdings Inc. | 9 | $301 |
| Dompe US, Inc. | 9 | $284 |
| Sun Pharmaceutical Industries Inc. | 15 | $278 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $220 |
| Glaukos Corporation | 2 | $168 |
| Mallinckrodt Hospital Products Inc. | 2 | $154 |
| Bausch & Lomb Americas Inc. | 5 | $102 |
| Rxsight Inc | 1 | $100 |
| Oyster Point Pharma, Inc. | 3 | $79 |
| Alcon | 3 | $77 |
| Novartis | 4 | $68 |
| AbbVie(2 entities) | 3 | $52 |
| Amgen | 2 | $47 |
| Astellas Pharma US Inc | 1 | $22 |
| Johnson & Johnson Vision Care, Inc. | 1 | $21 |
| Shire North American Group Inc | 1 | $20 |
| Sight Sciences, Inc. | 1 | $15 |
| Eyevance Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVELTYS$125
- LOTEMAX SM$125
- KXL System$125
- Photrexa$125
- ACTHAR$120
How this compares
$2,507 in reported general payments places this provider in the 65th percentile of 26 cornea and external diseases specialist providers in New York.
See all cornea and external diseases specialist providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 23 | $21,596 |
| XiidraLifitegrast | 19 | $19,034 |
| CequaCyclosporine | 15 | $14,014 |
| LumiganBimatoprost | 22 | $10,819 |
| Cyclosporine | 25 | $9,245 |
| CombiganBrimonidine Tartrate/Timolol | 11 | $7,790 |
| Prednisolone Acetate | 146 | $7,356 |
| Brimonidine Tartrate | 44 | $4,863 |
| ValacyclovirValacyclovir Hcl | 55 | $4,149 |
| Loteprednol Etabonate | 25 | $4,108 |
| Ofloxacin | 84 | $1,154 |
| Fluorometholone | 13 | $1,075 |
| Ketorolac Tromethamine | 18 | $1,040 |
| Doxycycline Hyclate | 35 | $874 |
| Timolol Maleate | 40 | $406 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $52 | $40,20556 claims |
| Bausch & Lomb Americas Inc.Xiidra | $102 | $19,03419 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $278 | $14,01415 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $220 | $4,10825 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 26 cornea and external diseases specialist providers in New York.
Other cornea and external diseases specialist in New York
- Christopher StarrNew York$294K
- Jessica CiralskyNew York$6K
- Nadia HaqqieNew York$6K
- Sirikishan ShettyNew York$3K
- Ksenia GomanNew York$2K
- Thomas VoNew York$2K
- Albert RudickNew York$2K
- Matthew NguyenNew York$2K
- Kimberly SippelNew York$882
- Samir JabbourNew York$619
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.